Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases
Authors' conclusion
This DUS provides descriptive data for initiators of liraglutide in the initial 5-year period following the launch of Saxenda® in the United Kingdom. Real-world use of Saxenda® and Victoza® raised no new safety concerns. Where assessment was possible, Saxenda® and Victoza® were mostly prescribed by physicians according to their approved indications.
Study context
- Population
- Adult liraglutide initiators without prior prescription in the 12 months before index date, UK CPRD Aurum and GOLD primary care databases
- Participants
- 604 vs 4,853
- Exposure
- Saxenda® vs Victoza® initiators
- Saxenda®n = 604
- Victoza®n = 4,853reference
- Outcome
- Real-world use of Saxenda® and off-label use of Victoza® for weight management, and Saxenda® posology
Methodological detailsnon-interventional, drug utilization study
- Non-interventional
- Drug utilization study
Main finding
As reported in the abstract
Saxenda® initiated according to weight loss indication (among those with available body weight)
Saxenda®
96.4%
- Saxenda® initiators with available body weight
- 306
- Patients with 24-week body mass index (BMI) data not adhering to Saxenda® stopping rule
- N < 5 of 16
- Patients with valid dose using Victoza® outside the diabetes indication
- N < 5 of 92
Observational data: associations, not effects.
Further findings
Female
Age
Duration of follow-up observation
Safety
- Real-world use of Saxenda® and Victoza® raised no new safety concerns
Original publication
Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases. Diabetes Obes Metab. Published 28 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →